Boots, PDA agree on 4.5 pc pay rise for multiple’s pharmacists

Date:

Share post:

Boots pharmacists will receive a pay rise of 4.5 per cent as the pharmacy multiple and PDA Union jointly announce this year’s pay settlement.

Following discussions between Boots management services and the PDA Union negotiators, the agreement was reached in relation to this year’s pay claim, effective from 1 November 2022.

The union also announced that those who have already had a pay increase on or since 1 August 2022, where that increase has been less than 4.5 per cent, a ‘top up’ increase will be provided, from 1 November 2022, to ensure that all eligible members of the bargaining unit receive a pay increment of not less than 4.5 per cent in 2022.

Boots and the PDA Union have agreed an increase to the pay of those above the maximum market range by 4 per cent with an additional 0.5 per cent non-consolidated payment.

This year pharmacists who are ineligible for the negotiated increase are:

  • Those who have joined on or since 1 August 2022
  • Those rated as not performing at EOY FY22
  • Trainee Pharmacists

It has also been agreed that “there will be a payment of £100 for pharmacists who work on a non-planned day with less than 48 hours’ notice to cover short notice absence.”

This would be based on £100 for an eight-hour day and pro-rated if the shift length is shorter.

“Boots and the PDAU recognise the current unique market circumstances within the community pharmacy sector relating to the pharmacist workforce and this has been reflected in the agreed package of pay and benefits. Consideration has been given to current price inflation along with the ability of the business to afford and sustain any agreed increases,” said the union.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...